AKT1 and neoplasm: The majority of human tumours harbour mutations promoting inappropriate activation of the Akt kinase, and therefore, inhibitors of Akt and its upstream activators including Class I PI3K are being evaluated in many cancer clinical trials (Liu et al, 2009; Vanhaesebroeck et al, 2012; Bauer et al, 2015).